Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*-Reference-Cited by-同舟云学术

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*

Published:2021-06-15 Issue:4 Volume:185 Page:745-755
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Murrell D.F.¹^ORCID,Patsatsi A.²,Stavropoulos P.³,Baum S.⁴,Zeeli T.⁵,Kern J.S.⁶,Roussaki‐Schulze A.‐V.⁷,Sinclair R.⁸,Bassukas I.D.⁹,Thomas D.¹⁰,Neale A.¹⁰,Arora P.¹⁰,Caux F.¹¹,Werth V.P.¹²^ORCID,Gourlay S.G.¹⁰,Joly P.¹³,

Affiliation:

1. Department of Dermatology St George Hospital University of New South Wales Faculty of Medicine Sydney NSW Australia

2. 2nd Dermatology Department Aristotle University Faculty of Medicine Papageorgiou General Hospital Thessaloniki Greece

3. 1st Department of Dermatology National and Kapodistrian University School of Medicine Athens Greece

4. Department of Dermatology Sheba Medical Center, Ramat Gan, Israel and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

5. Department of Dermatology Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

6. Dermatology Department The Royal Melbourne Hospital Faculty of Medicine, Dentistry and Health Sciences the University of Melbourne Melbourne VIC Australia

7. Department of Dermatology University General Hospital of Larissa Larissa Greece

8. University of Melbourne and Sinclair Dermatology Melbourne VIC Australia

9. Department of Skin and Venereal Diseases School of Health Sciences University of Ioannina Ioannina Greece

10. Principia Biopharma Inc., a Sanofi Company South San Francisco CA USA

11. Department of Dermatology Groupe Hospitalier Paris Seine‐Saint‐Denis AP‐HP Bobigny France

12. University of Pennsylvania and Corporal Michael J. Crescenz VAMC Philadelphia PA USA

13. Department of Dermatology Rouen University Hospital Centre de Référence des Maladies Bulleuses Autoimmunes, and INSERM U1234 Normandie University Rouen France

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20431

Reference29 articles.

1. Pemphigus: Current and Future Therapeutic Strategies

2. Prevalence Estimates for Pemphigus in the United States

3. Diagnosis and management of pemphigus: Recommendations of an international panel of experts

4. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications;Molecules;2023-12-11

2. Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective;Heliyon;2023-12

3. Applications of oxetanes in drug discovery and medicinal chemistry;European Journal of Medicinal Chemistry;2023-12

4. Blasenbildende Autoimmundermatosen – Klinik, Diagnostik und neue Therapieansätze;Aktuelle Dermatologie;2023-11

5. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases;Current Topics in Medicinal Chemistry;2023-11